BIX01294 suppresses PDAC growth through inhibition of glutaminase-mediated glutathione dynamics
Collectively, these findings suggest that BIX could be a potent therapeutic agent in patients with PDAC through its inhibition of GLS-mediated cellular redox balance.
Authors
- YongHwan Kim (ORCID: https://orcid.org/0000-0003-0621-5937)
- Yongsub Kim (ORCID: https://orcid.org/0000-0002-9334-4333)
- Sang‐Choul Im
- Jiyeon Kweon (ORCID: https://orcid.org/0000-0002-9116-8305)
- Dong‐Myung Shin (ORCID: https://orcid.org/0000-0002-0511-5750)
- Jin You (ORCID: https://orcid.org/0000-0002-2034-288X)
- Jaekyoung Son
- Jeong Kon Seo
- Hee Jae Bang
Institutions
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.molmet.2025.102113
- Citations
- 2
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Research Foundation of Korea
- Asan Institute for Life Sciences, Asan Medical Center